24. Ding MH, Liu L, Hu CX, et al. Expression of VEGF R2 and NRP-1 in non-small cell lung cancer and their clinical significance. Chin J Cancer Res, 2014, 26(6): 669-677.
[2]
25. Shim EJ, Chun E, Kang HR, et al. Expression of semaphorin 3A and neuropilin 1 in asthma. J Korean Med Sci, 2013, 28(10): 1435-1442.
[3]
26. Ferrara N, Gerber HP, Lecouter J. The biology of VEGF and its receptors. Nat Med, 2003, 9(6): 669-676.
[4]
36. Koh H, Tasaka S, Hasegawa N, et al. Vascular endothelial growth factor in epithelial lining fluid of patients with acute respiratory distress syndrome. Respirology, 2008, 13(2): 281-284.
[5]
37. Iain MJ, Mackenzie B, Tunnicliffe B. Blast injuries to the lung: epidemiology and management. Phil Trans R Soc B, 2011, 366(1562): 295-299.
41. 潘珍, 黎嘉文. 大剂量盐酸氨溴索对肺部的保护作用的 Meta 分析. 中国药房, 2014, 25(32): 3041-3045.
[9]
42. Seam N, Meduri GU, Wang H, et al. Effects of methylprednisolone infusion on markers of inflammation, coagulation, and angiogenesis in early acute respiratory distress syndrome. Crit Care Med, 2012, 40(2): 495-501.
[10]
43. Weekes CD, Beeram M, Tolcher AW, et al. A phase Ⅰ study of the human monoclonal anti-NRP1 antibody MNRP1685A in patients with advanced solid tumors. Invest New Drugs, 2014, 32(4): 653-660.
1. Smith JE. The epidemiology of blast lung injury during recent military conflicts: a retrospective database review of cases presenting to deployed military hospitals, 2003-2009. Philos Trans R Soc Lond B Biol Sci, 2011, 366(1562): 291-294.
4. Mellor SG, Cooper GJ. Analysis of 828 servicemen killed or injured by explosion in Northern Ireland 1970-84: the Hostile Action Casualty System. Br J Surg, 1989, 76(10): 1006-1010.
[16]
5. Bauman RA, Ling G, Tong L, et al. An introductory characterization of a combat-casualty-care relevant swine model of closed head injury resulting from exposure to explosive blast. J Neurotrauma, 2009, 26(6): 841-860.
[17]
6. Wolf SJ, Bebarta VS, Bonnett CJ, et al. Blast injuries. Lancet, 2009, 374(9687): 405-415.
[18]
10. Wong JM, Marsh D, Abu-Sitta G, et al. Biological foreign body implantation in victims of the London July 7th suicide bombings. J Trauma 2006, 60(2): 402-404.
15. Kirkman E, Watts S. Characterization of the response to primary blast injury. Philos Trans R Soc Lond B Biol Sci, 2011, 366(1562): 286-290.
[21]
18. Foster RR, Hole R, Anderson K, et al. Functional evidence that vascular endothelial growth factor may act as an autocrine factor on human podocytes. Am J Physiol Renal Physiol, 2003, 284(6): F1263-F1273.
[22]
21. Barratt S, Medford A R, Millar AB. Vascular endothelial growth factor in acute lung injury and acute respiratory distress syndrome. Respiration, 2014, 87(4): 329-342.
[23]
7. Skotak M, Wang F, Alai A, et al. Rat injury model under controlled field-relevant primary blast conditions: acute response to a wide range of peak overpressures. J Neurotrauma, 2013, 30(13): 1147-1160.
[24]
8. Kirkman E, Watts S, Cooper G. Blast injury research models. Phil Trans R Soc B, 2011, 366(1652): 144-159.
[25]
9. Joseph B, Bentley TL, Wessner KA, et al. Blast Overpressure in rats: recreating a battlefield injury in the laboratory. J Neurotrauma, 2009, 26(6): 827-840.
[26]
11. Chapman LE, Sullivent EE, Grohskopf LA, et al. Postexposure interventions to prevent infection with HBV, HCV, or HIV, and tetanus in people wounded during bombings and other mass casualty events-United States, 2008: recommendations of the Centers for Disease Control and Prevention and Disaster Medicine and Public Health Preparedness. Disaster Med Public Health Prep, 2008, 2(3): 150-165.
[27]
12. Clint BD. Force protection and infectious risk mitigation from suicide bombers. Mil Med, 2009, 174(7): 709-714.
[28]
13. Eshkol Z, Katz K. Injuries from biologic material of suicide bombers. Injury, 2005, 36(2): 271-274.
[29]
16. Medford AR, Millar AB. Vascular endothelial growth factor (VEGF) in acute lung injury (ALI) and acute respiratory distress syndrome (ARDS): paradox or paradigm?. Thorax 2006, 61(7): 621-626.
[30]
17. Kaner RJ, Crystal RG. Compartmentalization of vascular endothelial growth factor to the epithelial surface of the human lung. Mol Med, 2001, 7(4): 240-246.
[31]
19. Andrew RL, Nassif BN, Ann B, et al. Vascular endothelial growth factor receptor and coreceptor expression in human acute respiratory distress syndrome. J Crit Care, 2009, 24(2): 236-242.
[32]
20. Wild JR, Staton CA, Chapple K, et al. Neuropilins: expression and roles in the epithelium. Int J Exp Pathol, 2012, 93(2): 81-103.
[33]
22. Jia H, Cheng L, Tickner M, et al. Neuropilin-1 antagonism in human carcinoma cells inhibits migration and enhances chemosensitivity. Br J Cancer, 2010, 102(3): 541-552.
[34]
23. Fantin A, Herzog B, Mahmoud M, et al. Neuropilin 1 (NRP1) hypomorphism combined with defective VEGF-A binding reveals novel roles for NRP1 in developmental and pathological angiogenesis. Development, 2014, 141(3): 556-562.
[35]
27. Song J, Lu H, Zheng X, et al. Effects of vascular endothelial growth factor in recovery phase of acute lung injury in mice. Lung, 2015, 193(6): 1029-1036.
[36]
28. Yang Y, Hu SL, Xu XP, et al. The vascular endothelial growth factors-expressing character of mesenchymal stem cells plays a positive role in treatment of acute lung injury in vivo. Mediators Inflamm, 2016: ID2347938. Available at: https://www.hindawi. com/journals/mi/2016/2347938/.
[37]
29. Le A, Zielinski R, He C, et al. Pulmonary epithelial neuropilin-1 deletion enhances development of cigarette smoke-induced emphysema. Am J Respir Crit Care Med, 2009, 180(5): 396-406.
[38]
30. Kasahara Y, Tuder RM, Tarasevicienestewart L, et al. Inhibition of VEGF receptors causes lung cell apoptosis and emphysema. J Clin Invest, 2000, 106(11): 1311-1319.
34. Thickett DR, Armstrong L, Millar AB. A role for vascular endothelial growth factor in acute and resolving lung injury. Am J Respir Crit Care Med, 2002, 166(10): 1332-1337.
44. Jarvis A, Allerston CK, Jia H, et al. Small molecule inhibitors of the neuropilin-1 vascular endothelial growth factor A (VEGF-A) interaction. J Med Chem, 2010, 53(5): 2215-2226.
[46]
45. Eichholz A, Merchant S, Gaya AM, et al. Anti-angiogenesis therapies: their potential in cancer management. Onco Targets Ther, 2010, 3: 69-82.
[47]
46. Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med, 2006, 355(24): 2542-2550.
[48]
48. Hua F, Wang X, Zhu L. Terlipressin decreases vascular endothelial growth factor expression and improves oxygenation in patients with acute respiratory distress syndrome and shock. J Emerg Med, 2013, 44(2): 434-439.
